27-May-2026
Geron Shareholders Expand Equity Plan and Elect Directors
TipRanks (Wed, 27-May 5:04 PM ET)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Mon, 18-May 4:01 PM ET)
Globe Newswire (Tue, 12-May 9:31 AM ET)
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
Globe Newswire (Wed, 6-May 7:00 AM ET)
Geron Plans to Present at Upcoming Investor Conferences
Globe Newswire (Tue, 5-May 8:00 AM ET)
Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026
Globe Newswire (Wed, 22-Apr 7:00 AM ET)
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 14-Apr 4:05 PM ET)
Globe Newswire (Mon, 13-Apr 8:00 AM ET)
Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference
Globe Newswire (Mon, 6-Apr 8:00 AM ET)
Geron Announces Appointment of New Members to its Board of Directors
Globe Newswire (Thu, 26-Mar 8:00 AM ET)
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Geron trades on the NASDAQ stock market under the symbol GERN.
As of May 27, 2026, GERN stock price declined to $1.26 with 8,047,238 million shares trading.
GERN has a beta of 1.05, meaning it tends to be more sensitive to market movements. GERN has a correlation of 0.06 to the broad based SPY ETF.
GERN has a market cap of $808.32 million. This is considered a Small Cap stock.
Last quarter Geron reported $52 million in Revenue and -$.01 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.01.
In the last 3 years, GERN traded as high as $5.34 and as low as $1.04.
The top ETF exchange traded funds that GERN belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
GERN has underperformed the market in the last year with a price return of -15.4% while the SPY ETF gained +28.2%. GERN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -25.0% and -10.6%, respectively, while the SPY returned +9.7% and +1.1%, respectively.
GERN support price is $1.23 and resistance is $1.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GERN shares will trade within this expected range on the day.